Danilo Tagle,
Director, Office of Special Initiatives,
National Center for Advancing Translational Sciences at the NIH (NCATS)
Dan Tagle is Director of the Office of Special Initiatives at NCATS where he many coordinates efforts towards development of disruptive technologies in translational research. He obtained his Ph.D. in Molecular Biology and Genetics from Wayne State University School of Medicine. He was an NIH National Research Service Award postdoctoral fellow in Human Genetics at the University of Michigan. He has served on numerous committees, advisory boards, and editorial boards. He has authored many scientific publications and has garnered numerous awards, including more recently the Roscoe O. Brady Award for Innovation and Accomplishment, and the Henry J. Heimlich Award for Innovative Medicine.
Developing Novel Point of Care Diagnostics to Detect SARS-CoV-2
Wednesday, 14 December 2022 at 16:00
Add to Calendar ▼2022-12-14 16:00:002022-12-14 17:00:00Europe/LondonDeveloping Novel Point of Care Diagnostics to Detect SARS-CoV-2Point-of-Care and Rapid Diagnostics 2022 in Long Beach, CaliforniaLong Beach, CaliforniaSELECTBIOenquiries@selectbiosciences.com
The National Institutes of Health (NIH) launched the Rapid Acceleration
of Diagnostics (RADx) initiative to meet the needs for COVID-19
diagnostic and surveillance testing, and also to speed its innovation in
the development, commercialization, and implementation of new
technologies and approaches. The RADx Radical (RADx-rad) initiative is
one component of the RADx program which focuses on the development of
new, or non-traditional applications of existing approaches, to enhance
their usability, accessibility, and/or accuracy for the detection of
SARS-CoV-2. This presentation will elaborate on two RADx rad programs
led by the National Center for Advancing Translational Sciences on 1)
pivoting technologies being developed for the isolation of exosomes
towards screening and detection for SARS-CoV-2 viral infection due to
the similar physical and chemical properties between exosomes and
SARS-CoV-2 virus; and 2) developing novel biosensing capabilities using
electronic nose technologies to detect unique signatures of volatile
organic compounds (VOCs) of those with COVID-19 (Screening for COVID-19
by Electronic-Nose Technology (SCENT)).
Add to Calendar ▼2022-12-12 00:00:002022-12-14 00:00:00Europe/LondonPoint-of-Care and Rapid Diagnostics 2022Point-of-Care and Rapid Diagnostics 2022 in Long Beach, CaliforniaLong Beach, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2022-12-14 16:00:002022-12-14 17:00:00Europe/LondonDeveloping Novel Point of Care Diagnostics to Detect SARS-CoV-2Point-of-Care and Rapid Diagnostics 2022 in Long Beach, CaliforniaLong Beach, CaliforniaSELECTBIOenquiries@selectbiosciences.com
